v3.26.1
SEGMENT REPORTING
12 Months Ended
Sep. 30, 2025
SEGMENT REPORTING  
SEGMENT REPORTING

NOTE 14 – SEGMENT REPORTING

ASC 280, “Segment Reporting”, establishes standards for reporting information about operating segments on a basis consistent with the Company’s internal organizational structure as well as information about geographical areas, business segments and major customers in financial statements for details on the Company’s business segments. The Company uses the “management approach” in determining reportable operating segments. The management approach considers the internal organization and reporting used by the Company’s chief operating decision maker for making operating decisions and assessing performance as the source for determining the Company’s reportable segments. Management, including the chief operating decision maker, reviews operation results by the revenue of different products. Based on management’s assessment, the Company has determined that it has three operating segments as defined by ASC 280.

The Company, its subsidiaries, the VIEs and VIEs’s subsidiaries mainly manufactures and distributes diversified pharmaceutical and allied products, AI Solutions and Insurance Business in China. Currently no revenue is derived from international markets. The following table presents segment information for years ended September 30, 2025, 2024 and 2023, respectively:

For the Years ended September 30, 2025

Diversified

Pharmaceutical

and Allied

Insurance

  ​ ​ ​

Products

  ​ ​ ​

AI Solutions

  ​ ​ ​

Business

  ​ ​ ​

Total

Revenue

  ​ ​ ​

$

23,591,893

  ​ ​ ​

3,362,732

  ​ ​ ​

10,964,800

  ​ ​ ​

37,919,425

Cost of revenue

 

20,896,423

 

1,868,683

 

8,842,860

 

31,607,966

Gross profit

$

2,695,470

1,494,049

2,121,940

6,311,459

Depreciation and amortization

$

1,393,233

66,913

3,044

1,463,190

Capital expenditures

$

2,030,607

141,390

14,907

2,186,904

For the Years ended September 30, 2024

Diversified

Pharmaceutical

and Allied

Insurance

  ​ ​ ​

Products

  ​ ​ ​

AI Solutions

  ​ ​ ​

Business

  ​ ​ ​

Total

Revenue

  ​ ​ ​

$

25,097,951

  ​ ​ ​

$

  ​ ​ ​

  ​ ​ ​

$

25,097,951

Cost of revenue

 

20,983,196

 

 

 

20,983,196

Gross profit

$

4,114,755

$

$

4,114,755

Depreciation and amortization

$

1,237,230

$

$

1,237,230

Capital expenditures

$

3,931,471

$

$

3,931,471

For the Years ended September 30, 2023

Diversified

Pharmaceutical

and Allied

Insurance

  ​ ​ ​

Products Diversified

  ​ ​ ​

AI Solutions

  ​ ​ ​

Business

  ​ ​ ​

Total

Revenue

  ​ ​ ​

$

46,471,478

  ​ ​ ​

$

  ​ ​ ​

  ​ ​ ​

$

46,471,478

Cost of revenue

 

44,719,984

 

 

 

44,719,984

Gross profit

$

1,751,494

$

$

1,751,494

Depreciation and amortization

$

1,143,064

$

$

1,143,064

Capital expenditures

$

3,714,089

$

$

3,714,089